drugset / Trial / NCT00086710

Study of Enfuvirtide in HIV-Positive Subjects

NCT00086710

Phase 1 Completed 26 enrolled Trimeris Hoffmann-La Roche · collab
RandomizedCrossoverOpen-labelTreatment

Summary

A total of 26 patients will be admitted to the clinic where they will be dosed with each injection device. There will be a 7-day washout between doses and a 7-10 day follow-up period.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Enfuvirtide Peptide 90 mg Subcutaneous

Indications